Cullinan Therapeutics Inc. (CGEM)
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CGEM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $577.15M
- EPS (TTM)
- -$3.09
- Dividend yield
- None
- 52-week range
- 8.47 – 23.19
- Day range
- 8.80 – 9.43
- Volume / Avg
- 1.01M / 997.14K
- Beta
- —
- Shares outstanding
- 64.92M
52-week range
CGEM stock today
Cullinan Therapeutics (CGEM) closed at $8.89 on Nov 20, down 1.98% (-$0.18), versus the S&P 500's 3.70% decline. At this level, CGEM sits near the bottom of its 52-week range of $8.47 to $23.19: 61.7% below the high, set on Aug 26, 2026 and 5.0% above the low. CGEM is down 14.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.1%.
Cullinan Therapeutics has posted a net loss over the last twelve months (EPS of -$3.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cullinan Therapeutics
Company profileCullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Nadim Ahmed M.S.
- Headquarters
- Cambridge, MA
- Employees
- 109
- IPO year
- 2021
- Website
- cullinantherapeutics.com
Financial highlights
Full financialsCullinan Therapeutics reported a net loss of $219.9 million, compared with a loss of $167.4 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $18.94M |
| Growth | — | — | — | -100.00% | — |
| Net income | $-219.88M | $-167.38M | $-153.16M | $111.21M | $-65.57M |
| EPS (diluted) | — | — | $-3.69 | $2.38 | $-1.52 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$34.27+285.49%
- Strong buy 1
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.74 vs $-0.79
- Surprise
- +6.33%
CGEM news
All CGEM news- Cullinan Partner Taiho Completes FDA Filing For Zipalertinib Combo In First-Line Lung CancerNasdaqCGEM, WSO.B
- New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerGlobeNewswire
- Cullinan Therapeutics reports Q3 resultsSeeking Alpha
- Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Cullinan Therapeutics Announces Velinotamig Clinical Data Presented at ACR Convergence 2026Nasdaq
- Cullinan Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Cullinan Reports Phase 1b/2a Study Data For Velinotamig In SLE Patients; Stock UpNasdaqCGEM, BF.A
- Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026GlobeNewswire
Cullinan Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs CGEM |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs CGEM |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs CGEM |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs CGEM |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs CGEM |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs CGEM |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs CGEM |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs CGEM |
Indexes, lists and sector
Cullinan Therapeutics stock FAQ
What is Cullinan Therapeutics's stock price today?
CGEM last traded at $8.89 as of Nov 20, 4:00 PM EST, down 1.98% on the day. Prices are delayed at least 15 minutes.
Who is Cullinan Therapeutics's CEO?
Mr. Nadim Ahmed M.S. is the chief executive officer of Cullinan Therapeutics Inc., which has about 109 employees.
What is the CGEM 52-week high?
The 52-week high for CGEM is $23.19 and the 52-week low is $8.47. The stock is currently 61.7% below its high.